Evidence map›Paper›PMID 41935182›Full record

ArticleNPJ precision oncology2026

Comparison of gene fusion detection algorithms reveals frequently overlooked driver fusions in hematologic malignancies.

Zen Tamura, Yuki Saito, Yasunori Kogure, Yuji Oshikawa-Kumade, Suguru Fukuhara, Sumito Shingaki, Hirokazu Kariyazono, Yoshiya Kikukawa, Yuta Ito, Kota Mizuno and 7 more

Abstract read
In one paragraph

Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Zen Tamura *Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.
Yuki Saito *Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan. yuki.saito@keio.jp.
Yasunori KogureDivision of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.
Yuji Oshikawa-KumadeDivision of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.
Suguru FukuharaDepartment of Hematology, National Cancer Center Hospital, Tokyo, Japan.
Sumito ShingakiDivision of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.
Hirokazu KariyazonoDivision of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.
Yoshiya KikukawaDivision of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.
Yuta ItoDivision of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.
Kota MizunoDivision of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.
Yuichi ShiraishiDivision of Genome Analysis Platform Development, National Cancer Center Research Institute, Tokyo, Japan.
Kotoe KatayamaLaboratory of Sequence Analysis, Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Seiya ImotoLaboratory of Sequence Analysis, Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Koji IzutsuDepartment of Hematology, National Cancer Center Hospital, Tokyo, Japan.
Koichi MurakamiDivision of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.
Junji KoyaDivision of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.
Keisuke KataokaDivision of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan. kkataoka-tky@umin.ac.jp.

Funding

Japan Science and Technology Agency Moonshot R&D Program JPMJMS2022Japan Society for the Promotion of Science KAKENHI JP21H05051Japan Society for the Promotion of Science KAKENHI JP23K15313National Cancer Center Research and Development Funds 30-A-1
6 · The paper itself

Abstract

Accurate detection of driver gene fusions is essential for the diagnosis, treatment, and prognostic prediction of hematologic malignancies. Despite increasing reliance on RNA sequencing (RNA-seq) for fusion detection, its algorithms have not been sufficiently examined for their ability to detect clinically relevant driver fusions. We evaluated 12 algorithms using conventional RNA-seq from 170 cell lines and targeted RNA-seq from 26 cell lines and 165 clinical samples. The true positive rate, based on 61 and 24 driver fusion-cell line pairs for conventional and targeted RNA-seq, varied between 0.41-1 (median 0.81) and 0-1 (median 0.85), respectively. Many algorithms failed to detect fusions resulting from small deletions (including STIL::TAL1 and FIP1L1::PDGFRA), lowly expressed fusions, and IGH fusions (DUX4::IGH and IGH::NSD2). Targeted RNA-seq more sensitively detected driver fusions than conventional RNA-seq, especially lowly expressed ones. One algorithm, Arriba, detected all driver fusions. These findings will inform algorithm selection in clinical settings.

Identifiers

PMID41935182
PMCPMC13230599

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.